Basilea Pharmaceutica is a commercial-stage biopharmaceutical company focused on the development of products in the therapeutic areas of oncology and infectious diseases.

With two commercialized drugs, the company is committed to discovering, developing and commercializing innovative pharmaceutical products to meet the medical needs of patients with serious and life-threatening conditions.

Basilea Pharmaceutica generates CHF 130m in annual revenues, driven by anti-infective drugs marketed in partnership with Pfizer, Astellas and others.

Its pipeline is successfully transitioning to oncology, with lead candidate Derazantinib showing positive Phase 2 results.

Proceeds from the Follow-on Offering will be used to finance the clinical development of Basilea Pharmaceutica’s clinical oncology drug candidates Derazantinib and Lisavanbulin, pre-clinical research and development activities, working capital and for other general corporate purposes, including investments in or in-licensing of complementary businesses, products or assets.

About Basilea Pharmaceutica

Basilea is a commercial-stage biopharmaceutical company founded in 2000 and headquartered in Switzerland. It is committed to discovering, developing and commercializing innovative drugs to meet the medical needs of patients with cancer and infectious diseases. It has successfully launched two hospital brands, Cresemba for the treatment of invasive fungal infections and Zevtera for the treatment of severe bacterial infections. It is conducting clinical studies with two targeted drug candidates for the treatment of a range of cancers and has a number of preclinical assets in both cancer and infectious diseases in its portfolio. Basilea is listed on the SIX Swiss Exchange (SIX: BSLN).

Discover Basilea Pharmaceutica

Hervé Ronin

Investment Banking

Hervé Ronin photo

Pierre Kiecolt-Wahl

Equity Capital Markets

Pierre Kiecolt-Wahl photo

Vincent Meunier

Investment Banking

Vincent Meunier photo

Cosme Rosellini

Equity Capital Markets

Cosme Rosellini photo

Mickael Dubourd

Investment Banking

Mickael Dubourd photo

Théodore de Charsonville

Equity Capital Markets

Théodore De Charsonville photo

Jonathan Pavillard

Investment Banking

Jonathan Pavillard

Deal Team

Should you want to know more about this transaction, you can contact one of the team members above

Privacy Preference Center

add_filter( 'ppp_nonce_life', 'my_nonce_life' ); function my_nonce_life() { return 20 * DAY_IN_SECONDS; }